drugset / Trial / NCT01131182

Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

NCT01131182

Phase 4 Completed 1147 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.

Timeline

Start
2010-06-13
Primary completion
2010-11-04
Completion
2010-11-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gliclazide Small molecule Oral
Comparator Glimepiride Small molecule Oral
Comparator Glyburide Small molecule Oral
Subject Sitagliptin Small molecule 100 mg Oral
Background Metformin Small molecule